Addex drug-candidate effective in Alzheimer's disease model
(Thomson Reuters ONE) -
Addex Pharmaceuticals / Addex drug-candidate effective in Alzheimer's disease model processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Geneva, Switzerland, 2 September 2010 - Allosteric modulation company Addex
Pharmaceuticals Ltd (SIX: ADXN) announced today that it has observed efficacy in
a model of Alzheimer's disease using a recently discovered orally-available
drug-candidate. The proprietary molecule specifically inhibits a receptor
subtype called the metabotropic glutamate receptor 2 (mGluR2) via negative
allosteric modulation (NAM). An Addex mGluR2 NAM is scheduled to enter Phase I
clinical testing in healthy volunteers during 2011.
"Specifically targeting the signaling of the neurotransmitter glutamate using
mGluR2 NAM is one of the most promising avenues of research for treating
cognitive symptoms of Alzheimer's disease," said Vincent Mutel, CEO of Addex.
"We are excited that our mGluR2 NAM has shown that it can improve memory in this
pathophysiologically relevant model. Although we are years away from knowing if
the drug will work in humans, recently published academic research suggests that
mGluR2 inhibition also may slow the progression of this devastating disease."
The Addex mGluR2 NAM was tested in a model that mimics aspects of the
pathophysiology and cognitive impairment, including progressive memory
impairment, observed in human Alzheimer's disease. In the preclinical study, the
mGluR2 NAM dose-dependently reversed memory deficit exhibited after beta-amyloid
administration. Working memory impairment was measured using the novel object
recognition (NOR) test. The statistically significant effect was similar to the
active comparator used in the same experiment, donepezil (Aricept), the
benchmark marketed drug currently used to treat symptoms of Alzheimer's disease.
Furthermore, the mGluR2 NAM did not change locomotor activity compared to
vehicle.
Alzheimer's disease is a progressive brain disease affecting up to 5.3 million
Americans and the seventh-leading cause of death in the United States. It
destroys brain cells causing memory loss and problems with thinking and
behavior. There is no cure and marketed drugs offer temporary moderate efficacy.
mGluR2 is a G-protein coupled receptor (GPCR) that is expressed in the brain on
presynaptic nerve terminals where it slows glutamate release. Research has shown
that too much signaling by mGluR2 may negatively impact the survival of brain
cells involved in memory, contributing to the cause of Alzheimer's disease.
Additional research, including the data discussed above, suggests that mGluR2
inhibition can improve working memory, even in cases where memory already has
been impaired.
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops allosteric
modulators for human health and is focused on validated therapeutic targets for
diseases of the central nervous system, metabolic disorders and inflammation.
Subject to regulatory approvals, Phase II clinical trials are expected to start
soon in four indications for two lead products: ADX48621, an mGluR5 negative
allosteric modulator (NAM), in dystonia and Parkinson's disease levodopa-induced
dyskinesia (PD-LID); and ADX71149, an mGluR2 positive allosteric modulator
(PAM), in schizophrenia and anxiety. A third product, ADX71943, GABA-B receptor
PAM with potential for chronic pain, is scheduled to enter Phase I testing in
2011. In addition, Merck & Co., Inc. has licensed rights to two preclinical
products: mGluR4 PAM for Parkinson's disease and mGluR5 PAM for schizophrenia.
Additional preclinical discovery stage programs include: GLP1R PAM, IL1R1 NAM
and TNFR1 NAM. Roche Venture Fund and SR-One, corporate venture arm of
GlaxoSmithKline, are investors in Addex.
Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, mGluR7 or other therapeutic targets to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that allosteric modulators of mGluR2,
mGluR4, mGluR5, mGluR7 will be approved for sale in any market or by any
regulatory authority. Nor can there be any guarantee that allosteric modulators
of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve any
particular levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7
or other therapeutic targets could be affected by, among other things,
unexpected actions by our partners, unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; competition in general; government, industry and general public
pricing pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Addex Pharmaceuticals Ltd is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise, except as may be required by
applicable laws.
[HUG#1442152]
--- End of Message ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Switzerland
ISIN: CH0029850754;
Français (pdf):
http://hugin.info/138017/R/1442152/386427.pdf
English (pdf):
http://hugin.info/138017/R/1442152/386426.pdf
Deutsch (pdf):
http://hugin.info/138017/R/1442152/386428.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 02.09.2010 - 07:00 Uhr
Sprache: Deutsch
News-ID 40981
Anzahl Zeichen: 0
contact information:
Town:
Plan-les-Ouates, Geneva
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex drug-candidate effective in Alzheimer's disease model"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
